Vivid Genomics is dedicated to helping pharmaceutical companies improve the probability of clinical trial success by identifying, enrolling, and stratifying the right patients.
Promise in Dementia Drug Development Despite Failures
Drug development in neurodegenerative disease is challenging, and Alzheimer’s disease specifically is notorious for failures; there have been ~150 failed attempts in the last 20 years, at an estimated cost of $5.5B per successful drug from pre-clinical to phase 3. Yet academic researchers, governments, and pharmaceutical companies continue to innovate and invest in development, because the need is so great.
Genomic Biopsy™
Vivid Genomics enables pharma companies to select and stratify the right patients for their clinical trials, increasing the probability of trial success and drug approval. We use machine learning and genomics to develop blood-based, genetic tests (“Genomic BiopsyTM”) for neurodegenerative diseases.
Inquiries regarding our Services
Contact Vivid Genomics to advance your research or clinical practice with our clinically validated assays.